Northbrook, IL 60062 -- (SBWIRE) -- 12/07/2022 -- The Global research report "US General Anesthesia Drugs Market by Route of Administration (Intravenous and Inhalational), End User (Hospitals, Ambulatory Surgery Centers) - Forecast to 2025", published by MarketsandMarkets™, The US general anesthesia drugs market size is projected to reach USD 2.4 billion by 2025 from USD 2.0 billion in 2020, at a CAGR of 3.4% during the forecast period. The rising prevalence of cancer, rapid growth in geriatric population, and increasing number of emergency surgeries are some of the major factors driving the growth of the US general anesthesia drugs.

Browse in-depth TOC on "US General Anesthesia Drugs Market"

39 – Tables
43 – Figures
118 – Pages

Key Market Player

The US general anesthesia drugs market is dominated by a few established players such as Baxter International Inc. (US), Hikma Pharmaceuticals plc (UK), Pfizer Inc. (US), Piramal Enterprises Limited (India), AbbVie (US), Fresenius SE & Co. KGaA (Germany), Par Pharmaceutical (US), Teva Pharmaceuticals (Israel), Viatris/Mylan (US), Novartis AG (US), Abbott Laboratories (US), AstraZeneca plc (US), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline plc (UK), Gilead Sciences, Inc. (US), Bayer AG (Germany), Merck & Co., Inc. (Germany), Sanofi (France), Heritage Pharmaceuticals Inc. (US), Akorn (US), and Apotex (Canada) among others.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=713

Drivers: Shift from parenteral to enteral nutrition

Enteral feeding is the delivery of artificial nutrients or medication through the gastrointestinal tract (including the esophagus, stomach, and the small and large intestine) to the organs. On the other hand, Parenteral feeding uses the central or peripheral veins to intravenously deliver nutrients or medication into the bloodstream with the use of a catheter. Furthermore, the cost of enteral nutrition is lower than parenteral nutrition. The average cost of enteral nutrition per patient per day is about 40% of that of parenteral nutrition. These benefits have led to a significant increase in the adoption of enteral feeding in various treatment regimes.

Restraints: Complications associated with enteral feeding devices

Enteral feeding is an efficient and cost-effective option for providing clinical nutrition to patients. However, there are a few complications associated with the use of these devices, which result in additional healthcare costs. Most of the complications associated with enteral feeding are minor, but some can be quite serious. The metabolic complications of enteral nutrition are very similar to those occurring during parenteral nutrition, despite their lower incidence and severity. Careful monitoring can help reduce or prevent these problems. However, these concerns, coupled with the mortality associated with these complications, act as a restraint to the greater adoption of enteral feeding devices

The rising prevalence of cancer, rapid growth in geriatric population, and increasing number of emergency surgeries are some of the major factors driving the growth of the US general anesthesia drugs.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=713

Intravenous anesthesia drugs accounted for the largest share in the market in 2019.

Based on the route of administration, US general anesthesia drugs market is categorized into inhalational anesthesia drugs and intravenous anesthesia drugs. The inhalational anesthesia drugs is further categorized into sevoflurane, desflurane, isoflurane and nitrous oxide. Similarly, intravenous anesthesia drugs are further categorized into propofol, benzodiazepines, ketamine, methohexital sodium and others intravenous general anesthesia drugs. The intravenous segment accounted for the largest share of the market. General intravenous anesthesia drugs are less expensive and do not require expensive machines for administration which contributes to the high market share of the segment.

Hospitals accounted for the largest share in the market in 2019

Based on end user, the US general anesthesia drugs market has been segmented into hospitals and ambulatory surgery centers. The hospitals segment accounted for the largest share of the market in 2019. The massive patient footfall in hospitals and the increasing number of surgeries performed in these facilities are the factors responsible for the largest share of the segment.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=713